EUVIMEDEUVIMED entdecken
Crossref

Implante de dexametasona intravítreo transquirúrgico en pacientes con vitreorretinopatía proliferativa

Jeniffer Trenado-Luna, Gerardo Rivera-Arroyo, Elizabeth Baqués-Guillén, César Ramos-Roldán, José Ma Arroyo-González, Lucila García-Chávez, José F Valdez-López, Pedro Escalera-Arroyo

Cirugía y Cirujanos · 2023

DOI: 10.24875/ciru.22000111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cirugía y Cirujanos, 2023. Verfasst von Jeniffer Trenado-Luna und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Retina y Vítreo, Hospital Central Militar, Ciudad de México, México. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative, Retinal Detachment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the anatomical results in patients with rhegmatogenous retinal detachment, at least grade B of proliferative vitreoretinopathy, and with a trans-surgical dexamethasone implant vs the control group. We also assessed the diminution of proliferative vitreoretinopathy and the final visual acuity (VA).

Method

The patients were evaluated clinically and with optical coherence tomography for 10 months. Logistic regression analyses were performed to evaluate the effect of the dexamethasone implant on retinal detachment. Correlational analyses were explored depending on the variables' distribution, and an independent samples t-test was used to compare the VA in both groups.

Results

The study included 38 eyes of patients with proliferative vitreoretinopathy: 18 with the implant and 20 for the control group. The evaluation of the main objective showed significant differences (p < 0.05) in the anatomical success between the two groups (61.1% vs. 20%, treatment vs. control); odds ratio of 6.29; 95% confidence interval: 1.5- 26.8; p = 0.013; Nagelkerke's R2 = 0.225. The t-test showed a significant difference in the final VA of the patients (t = 2.047; df = 36; p = 0.048; Cohen's d = 0.66).

Conclusions

Retinal redetachment was less frequent, and better VA was observed, in patients with the dexamethasone implant in comparison with the control group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitreoretinopathy, ProliferativeRetinal DetachmentHumansVitrectomyRetinaDexamethasoneRetrospective Studies

Stichwörter der Autor:innen

Desprendimiento de retinaDexametasonaDexamethasoneIntravitreal injectionInyección intravítreaProliferative vitreoretinopathyRetinal detachmentVitreorretinopatía proliferativa

Substanzen

Dexamethasone

Autor:innen und Institutionen

  • Departamento de Retina y Vítreo, Hospital Central Militar, Ciudad de México, México.

Zitieren

APA

Trenado-Luna, J., Rivera-Arroyo, G., Baqués-Guillén, E., Ramos-Roldán, C., Arroyo-González, J. M., García-Chávez, L., Valdez-López, J. F., & Escalera-Arroyo, P. (2023). Implante de dexametasona intravítreo transquirúrgico en pacientes con vitreorretinopatía proliferativa. Cirugía y Cirujanos. https://doi.org/10.24875/ciru.22000111

Vancouver

Trenado-Luna J, Rivera-Arroyo G, Baqués-Guillén E, Ramos-Roldán C, Arroyo-González JM, García-Chávez L, et al. Implante de dexametasona intravítreo transquirúrgico en pacientes con vitreorretinopatía proliferativa. Cirugía y Cirujanos. 2023. doi:10.24875/ciru.22000111

BibTeX
@article{TrenadoLuna2023,
  author = {Trenado-Luna, Jeniffer and Rivera-Arroyo, Gerardo and Baqués-Guillén, Elizabeth and Ramos-Roldán, César and Arroyo-González, José Ma and García-Chávez, Lucila and Valdez-López, José F and Escalera-Arroyo, Pedro},
  title = {Implante de dexametasona intravítreo transquirúrgico en pacientes con vitreorretinopatía proliferativa},
  journal = {Cirugía y Cirujanos},
  year = {2023},
  doi = {10.24875/ciru.22000111}
}
Kostenlos starten →